Refine by
Preclinical Trial Suppliers & Manufacturers
93 companies found
based inSunrise, FLORIDA (USA)
U.S. Stem Cell, Inc. (OTC:USRM) is an emerging leader in the worldwide development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions. Based in Sunrise, Florida, the Company has developed a clinical ...
MyoCell SDF-1 has received approval from the FDA to begin human clinical trials and is intended to be an improvement to MyoCell. The myoblast cells to be injected are gene-modified prior to injection by an adenovirus vector so that they will release ...
based inBroomfield, COLORADO (USA)
Founded in 2009, Flagship Biosciences, Inc., is a technology-driven spatial biology and biomarker services company delivering the most accurate and informative data available. We are revolutionizing biomarker analysis to improve drug development and ...
Your next pathology-based CDx starts here. With the complexity of therapies increasing, the need for a robust companion diagnostic (CDx) has never been higher. Advances in tissue analysis technologies now require a more quantitative, accurate, and ...
based inDundee, UNITED KINGDOM
Vascular Flow Technologies (VFT) has evolved into an ISO 13485 Medical Device Development company with unique insight and capabilities in pre-clinical development and testing. VFT developed and patented its novel Spiral Laminar Flow™ (SLF) ...
based inPasadena, CALIFORNIA (USA)
LIXTE is a drug discovery company that has a developed unique, proprietary, first in-class protein phosphatase inhibitor, LB-100, our lead clinical compound. LB-100 has potential widespread use as an anti-cancer agent when used alone and in ...
Pre-clinical studies showed that LB-100 alone inhibits a spectrum of human cancers but when combined with standard cytotoxic drugs and/or radiation, LB-100 potentiates their effectiveness against hematologic and solid tumor cancers without enhancing ...
based inOxford, UNITED KINGDOM
Oxford Vacmedix was established in 2012 as a spinout from Oxford University. Its aim is to develop therapeutic agents for the treatment of cancer based on the invention of Professor Shisong Jiang – Recombinant Overlapping Peptides (ROP). These ...
based inCardiff, UNITED KINGDOM
Alesi Surgical was founded in 2009 to develop and commercialise products that improve the safety, efficacy and outcomes of surgical procedures. The company is a spin-out from the Welsh Institute for Minimal Access Therapy (WIMAT), a leading surgical ...
Alesi Surgical and WIMAT are co-located and collaborate on research and development, testing, product design, pre-clinical evaluation and post-market clinical follow-up. This provides a unique level of access to experienced surgeons, surgical ...
based inFremont, CALIFORNIA (USA)
EnColl Corporation, established in 1994, is a California corporation that develops, manufactures and markets Type-I collagen-based products. EnColl uses its patented technology for the preparation of high purity and charge modified collagen (U.S. ...
based inHradec Králové, CZECH REPUBLIC
GENERI BIOTECH was established in 1995, originally as a facility for production of oligonucleotides. We are focusing on R&D, manufacturing and selling of own proprietary products such as real-time PCR CE IVD kits, Life Sciences products and ...
based inNew York, NEW YORK (USA)
IN8bio was founded in 2016 with the mission of developing novel therapies to address cancer. The company is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T-cell product ...
based inFoster City, CALIFORNIA (USA)
PointCross Life Sciences is a wholly-owned subsidiary of PointCross Inc. We are a global technology company providing the life sciences industry with solutions in big data analytics, management, visualization, and warehousing. Our offerings reduce ...
based inUnion City, CALIFORNIA (USA)
Fibralign is an award-winning, commercial-stage, Stanford-spinout that designs, develops and produces novel therapeutic medical devices to address major unmet medical needs. Based in the San Francisco Bay Area, the company’s team has established GMP ...
Fibralign is developing a pipeline of compelling novel products which are based on its proprietary Nanoweave® scaffolding platform that can be tailored to address a wide range of high-value applications. Nanoweave technology provides the means ...
based inGrove City, OHIO (USA)
Forge is developing innovative gene therapies that aim to help patients suffering from devastating rare diseases. Forge is building capacity to directly address the growing demand for gene therapy manufacturing. Forge is currently building the ...
Plasmid DNA is an essential component of gene therapy development and the starting point of Forge’s idea-to-impact manufacturing services to accelerate gene therapy programs from preclinical through clinical and on to commercial manufacturing. ...
based inParis, FRANCE
Abivax develops innovative treatments modulating the body’s natural immune system machinery to treat patients with chronic inflammatory diseases, viral infections and cancer. As a clinical-stage company, Abivax leverages its immune enhancing and ...
ABX196 has been developed as a synthetic agonist of iNKT cells from a proprietary platform technology that identifies cells with immune enhancing potential in cancer ...
based inMississauga, ONTARIO (CANADA)
Award-winning, Clinical Stage/Life-Sciences company focused on the drug discovery and development of next-generation targeted therapeutics within the endocannabinoid system and specific brain receptors. The company is targeting anxiety, depression, ...
Mentanine®, supported by (cannabidiol “CBD” + IP formula) – molecules bond and synergistically attach to PPAR receptors allowing the formula to cross the blood-brain barrier (BBB) to target the central nervous ...
based inSouth Melbourne, AUSTRALIA
BioDiem is an Australian biopharmaceutical company that is focused on developing and commercialising vaccines and infectious disease therapies. Our business model is to generate income from partnerships including with other vaccine and infectious ...
A core technology advantage: Live Attenuated Influenza Virus (LAIV) vaccine. BioDiem’s lead asset is the Live Attenuated Influenza Virus (LAIV) vaccine technology. Our LAIV vaccine licensing business involves out-licensing of the ...
based inPoitiers, FRANCE
BioCydex is at the cutting edge of research providing solutions and technologies which when implemented radically improve the developments of your products in the field of Human Health and Biological engineering. At BioCydex, fundamental priorities ...
Vectisol® is dedicated to the preservation of organs, tissues and cells. This molecular complex limits the deleterious effects of the ischemia-reperfusion ...
based inGeumcheon-gu, SOUTH KOREA
We, ROKIT Healthcare, endeavor and strive to change the world with our customized artificial organ platforms. We want to provide the safest and effective organ regeneration platform services with our expertise in regenerative medicine. I believe ...
based inCambridge, UNITED KINGDOM
CN Bio is a leading bioengineering company specialising in single and multi-organ microphysiological systems and innovative lab technologies. We aim to provide systems that generate clinically translatable data that can enhance the development of ...
Generate human-specific pre-clinical safety and efficacy data with pioneering PhysioMimix single- and multi-organ-on-a-chip ...
based inNorth Brunswick, NEW JERSEY (USA)
Ascendia Pharmaceuticals specializes in the invention and development of specialty pharmaceutical products and novel formulation technologies. We provide formulation, analytical, and manufacturing services to pharmaceutical companies, working ...
Ascendia specializes in the development of market suitable formulations for poorly water soluble drug substances. Based on the pre-formulation data package and the delivery requirements for the product, we recommend a comprehensive formulation ...
based inBoston, MASSACHUSETTS (USA)
CervoMed is a clinical stage company dedicated to the development and commercialization of drug treatments for neurodegenerative diseases with a focus on the early stages of the neurodegenerative process. Until August 2023, CervoMed was known as ...
Our lead product candidate, Trans sodium crocetinate (TSC), is being developed to enhance the diffusion of oxygen to tissues with low oxygen levels, also known as hypoxia, a serious complication of many of medicine’s most intractable and ...